Ashvattha Therapeutics Presents Transformative Anti-Angiogenesis Treatment for Retinal Disorders at ARVO 2021
Ashvattha announced the presentation of a virtual poster supporting the development of its proprietary HDT, D-4517, for treatment of AMD at the 2021 ARVO Annual Meeting.